Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1998-1-14
|
| pubmed:abstractText |
Chronic beryllium disease (CBD) provides a model system in which to evaluate the antigen-stimulated, cell-mediated, immune response that leads to granulomatous lung disease. We hypothesized that beryllium salts would stimulate bronchoalveolar lavage (BAL) cell release of tumor necrosis factor-alpha (TNF-alpha) and lnterleukin-6 (IL-6), and their soluble receptors, soluble TNF receptor I (sTNF RI), sTNF RII, and sIL-6R and that chronic exposure to antigen would increase production of soluble receptors in the serum and BAL fluid (BALF) of beryllium-sensitized and CBD patients. We have demonstrated (1) similar constitutive TNF-alpha, IL-6, and soluble receptor production by control subjects and CBD patients, (2) a BeSO4-stimulated increase in TNF-alpha and IL-6 production by CBD-derived BAL cells, and (3) a BeSO4-induced decrease in sTNF RII production by BAL cells from control subjects. We measured increased serum sTNF RI and serum and BALF sIL-6R in beryllium-sensitized subjects and increased sTNF RI and RII in serum and sIL-6R and sTNF RII and BALF in CBD patients. These changes correlated with pulmonary lymphocytosis and clinical measures of disease severity, indicating that soluble receptors may reflect disease status.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Beryllium,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/beryllium sulfate
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
156
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1884-91
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:9412570-Adult,
pubmed-meshheading:9412570-Berylliosis,
pubmed-meshheading:9412570-Beryllium,
pubmed-meshheading:9412570-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:9412570-Chronic Disease,
pubmed-meshheading:9412570-Female,
pubmed-meshheading:9412570-Forced Expiratory Volume,
pubmed-meshheading:9412570-Humans,
pubmed-meshheading:9412570-Hypersensitivity,
pubmed-meshheading:9412570-Interleukin-6,
pubmed-meshheading:9412570-Male,
pubmed-meshheading:9412570-Middle Aged,
pubmed-meshheading:9412570-Pulmonary Gas Exchange,
pubmed-meshheading:9412570-Receptors, Interleukin-6,
pubmed-meshheading:9412570-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:9412570-Solubility,
pubmed-meshheading:9412570-Tumor Necrosis Factor-alpha,
pubmed-meshheading:9412570-Vital Capacity
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease.
|
| pubmed:affiliation |
National Jewish Medical and Research Center, Division of Environmental and Occupational Health Sciences, Denver, Colorado, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|